

IN THE CLAIMS:

Cancel claims 1-17 without prejudice or disclaimer.

Please amend the claims as shown below:

Claims 1-17 (canceled)

Claim 18 (currently amended): ~~A method~~ Method of treating disorders involving human bronchocontraction, ~~chosen~~ selected from the group consisting of asthma, asthma ~~and disorders related disorders thereto~~, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease, the method comprising:

administering one or more compounds having agonist activity to a 5-HT₄ receptor,
wherein said one or more compounds have the capacity of reducing pathological bronchocontraction by at least 30%, ~~preferably at least 60%, and most preferably at least 90%.~~

Claim 19 (currently amended): ~~A method~~ Method of claim 18, wherein said one or more compounds are ~~chosen~~ selected from the group ~~comprising~~ consisting of the following 5-HT₄ receptor agonists:

a) benzamides ~~benzmid~~es containing the structural element 4-amino-5-chloro-2-methoxy benzamide, optionally having a basic nitrogen in a side chain from the amide nitrogen, ~~said basic nitrogen often being a part of a sterically locked system, preferably BRL 20627, BRL 24682, BRL 24924, Cisapride, Metoclopramide, ML 1035, Mosapride, RO76186, Renzapride, RS 67506, Cinitapride, SB 205149, SC 49518, SC 52491, SC 53116, SDZ 216,454, TKS 159, Y-34959, YM 09151, YM 47813, and Zaco~~pride;


b) benzoic acid esters:
~~preferably ML 10302, RS 57639, and SR 59768;~~

c) a 2, 3-dihydro-benzofuran-7-carboxamide compound, preferably ~~ADR-932,~~
~~Prucalopride (=R-093877), and SK-951;~~


d) ~~benzofuranes~~ benzofuranes; and

e) benzothiophenes[~~[,]~~];

f) the benzodioxan




g) the benzoic acid antagonist RS 23597 (~~an ester~~) transformed to an agonist by
conversion to a ketone




e.g. ~~RS 67333 and RS 17017.~~

h) ~~naphtalimides, preferably RS-56532;~~



i) benzindolones;

j) compounds in which the amide function has been replaced with an oxadiazol ring;





~~preferably YM-53389;~~

k) benzimidazolone-1-carboxamides

~~preferably BIMU-1, BIMU-8, DAU-6215, and DAU-6236;~~

l) the carboamides




m) indols ~~Indols, preferably 5-methoxytryptamine, 2-methylserotonine, and 5-hydroxy-N,N-di-methyltryptamine;~~

n) compounds ~~Compounds~~ quartenized on the nitrogen in the side chain[[:]];]



o) bensokinolinones

p) 5-carboxamidotryptamine (5-CT), with the structural formula:




Q) 5-HT, 3-Me-8-OH-DPAT, 8-OH-DPAT (8-hydroxy-2-dipropylaminotetralin), RS 23597-190, RS 67532, RU 28253, SB 204070, Bufotenine, 5-MeO-N,N,DMT, GR 113,808,


α -methyl-5-HT, arylcarbamate derivatives of 1-piperidineethanol, arylcarbamate derivatives of 1-piperidineethanol, 4-amino-5-chloro-2-methoxybenzoic acid esters, 4-amino-5-chloro-2-methoxy-N-((2S,4S)-1-ethyl-2-hydroxymethyl-4-pyrrolidinyl)benzamide, thiophene carboxamide derivatives 3 (a-j), 5.azabicyclo(x.y.z) derivatives, 2-piperazinylbenzoxazole derivatives, 2-piperazinylbenzothiazole derivatives (e.g. VB20B7), Sandoz compound 1b, clebopride, 2-piperidinmethylethers of benzimidazole, zelmec,




oxadiazolone based
 substance






kinolines







~~particularly~~






Q





benzopyranes

~~particularly~~



and derivatives and pharmaceutically acceptable salts thereof.

Claim 20 (currently amended): The method ~~Method~~ of claim 18, wherein said one or more compounds is VB20B7, RS67333, BIMU 1, BIMU 8, 5-methoxytryptamine, Zacopride, RS565323, Mosapride, BRL 24924, or SC 53116.

Claim 21 (currently amended): The method ~~Method~~ according to claims 18-20, wherein said disorder involving bronchocontraction is asthma and disorders related thereto.

Claim 22 (new): The method according to claim 18, wherein said one or more compounds have the capacity of reducing pathological bronchocontraction by at least 60%.

Claim 23 (new): The method according to claim 18, wherein said one or more compounds have the capacity of reducing pathological bronchocontraction by at least 90%.

Claim 24 (new): The method according to claim 19, wherein said benzamide is selected from the group consisting of BRL 20627, BRL 24682, BRL 24924, Cisapride, Metoclopramide, ML-1035, Mosapride, RO76186, Renzapride, RS 67506, Cinitapride, SB 205149, SC-49518, SC-52491, SC-53116, SDZ 216,454, TKS 159, Y-34959, YM-09151, YM-47813, and Zacopride.

Claim 25 (new): The method according to claim 19, wherein said benzoic acid esters is selected from the group consisting of ML 10302, RS 57639, and SR 59768.

Claim 26 (new): The method according to claim 19, wherein said 2, 3-dihydro-bensofuran-7-carboxamide compound is selected from the group consisting of ADR 932, Prucalopride (=R 093877), and SK-951.

Claim 27 (new): The method according to claim 19, wherein said naphtalimides is RS 56532.

Claim 28 (new): The method according to claim 19, wherein said compounds in which the amide function has been replaced with an oxadiazol ring is YM-53389.

Claim 29 (new): The method according to claim 19, wherein said benzimidazolone-1-carboxamides are selected from the group consisting of BIMU 1, BIMU 8, DAU 6215, and DAU 6236.

Claim 30 (new): The method according to claim 19, wherein said indols are selected from the group consisting of 5-methoxytryptamine, 2-methylserotonine, and 5-hydroxy-N,N-dimethyltryptamine.

Claim 31 (new): The method according to claim 19, wherein said 5-HT₄ receptor agonists are represented by the following chemical formulas:

